ELK1
ELK1 is a transcription factor in the ETS oncogene family, which is a group of genes that encode transcription factors related to the transformation and transcription of certain genes that can lead to cancer. ELK1 is involved in the regulation of gene expression by signal transduction pathways, particularly those stimulated by mitogens and growth factors. It plays a crucial role in the MAPK/ERK pathway, which is important for cell proliferation, differentiation, and survival.
Function
ELK1 functions by binding to a specific DNA sequence known as the ETS-binding site (EBS) and regulates the expression of genes that are involved in cell cycle, apoptosis, and cell differentiation. It is activated through phosphorylation by MAP kinases in response to various extracellular signals. Once activated, ELK1 can dimerize with SRF (serum response factor) and bind to the serum response element (SRE) in the promoters of target genes, such as c-fos, initiating their transcription.
Structure
The structure of ELK1 includes several domains essential for its function: the ETS domain, responsible for DNA binding; the B-box, necessary for transcriptional activation; and the C-terminal domain, which includes the points of phosphorylation by MAP kinases. This phosphorylation is critical for ELK1's activation and function.
Role in Disease
Alterations in the activity or expression of ELK1 have been implicated in various cancers, including prostate cancer, breast cancer, and glioblastoma. Its role in these diseases often relates to its function in controlling cell proliferation and survival, making it a potential target for therapeutic intervention.
Research and Therapeutic Potential
Given its central role in cell growth and survival pathways, ELK1 is a subject of research for potential therapeutic interventions in cancer and other diseases related to dysregulation of the MAPK/ERK pathway. Inhibitors targeting the pathway upstream of ELK1 or directly interfering with ELK1's function could provide new avenues for treatment.
See Also
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD